Toxicity and Adverse Outcomes of Letermovir vs. Valganciclovir Cytomegalovirus (CMV) Prophylaxis in Lung Transplantation (IDWeek 2025) - Sep 3, 2025 - Abstract #P-2120; Pres time: Oct 22, 2025; 12:15 PM - 01:30 PM; Location: Poster Hall B4-B5; No abstract available
Adverse events • Cytomegalovirus Infection • Infectious Disease
|
|
Dimitrios G. Moshovitis, BA; Andres Franceschi Coll, MD; Ahmad Nawlo, MD; Marco Aurelio Diaz, MD; Christine Atallah, MD; Paul Sakr, MD; Hassan Alshaker, MD; Rayven Frierson, BS; Djenabou Sow, BS; Jawad Safiia, Pharm. B; Pritha Sen, MD; Dimitrios Farmakiotis; Sophia Koo, MD, SM
|